Zdrowie i gospodarka · 25/07/2022
FDA Releases Final Guidance on Responding to Complete Response Letters for ANDA Applications
The FDA has issued a final guidance to help pharmaceutical companies respond to complete response letters for abbreviated new drug applications, outlining potential courses of action and factors to consider when requesting an extension to respond to the letter.